NY-BEHAVOX
2.6.2020 14:02:13 CEST | Business Wire | Press release
Behavox , which provides the world’s only AI-based end-to-end data operating platform that enables enterprises to aggregate, analyze, and act on their entire organization's data, today announced that Danske Bank A/S , Denmark’s largest, full-service bank, has selected Behavox as its platform for electronic and audio communication compliance supervision.
As Behavox’s momentum in the finance sector continues to grow globally, Danske Bank represents its latest customer win in Europe. Danske Bank’s decision to select Behavox stems from the banking giant’s strategy to grow its business on the back of advanced data analytics – analytics that will help Danske Bank become faster, smarter, and more agile in supporting hundreds of branch sites and millions of clients throughout the Nordics.
According to Simon Kingsbury, Executive Vice President at Danske Bank, the use of effective data analytics to strengthen regulatory compliance controls is part of the wider efforts to modernize banking. Compliance efforts must be executed quickly, efficiently, and intelligently. To achieve greater agility and speed, particularly in a macroeconomic environment with increasingly distributed work environments, Mr. Kingsbury said Danske Bank is using Behavox to establish compliance operations that are fueled by cutting-edge artificial intelligence and machine learning. The Behavox Compliance solution’s AI and ML capabilities provide powerful data analytics to help Danske Bank identify immediate actions for ensuring regulatory compliance.
“At Danske Bank, compliance is not a checkbox,” said Mr. Kingsbury. “It is an integral part of our strategy in a competitive and demanding regulatory environment.”
Behavox supports financial regulatory compliance requirements for Dodd-Frank, MAR, FCPA, SMR, and MiFID II. Its solutions meet the requirements of the most demanding global regulators, such as FINRA, CFTC, and FCA. After conducting extensive due diligence, Mr. Kingsbury and the Danske Bank team selected Behavox because of its performance, the ability to deploy quickly, and key functional benefits.
“Danske Bank is our latest European customer with a vision to enhance risk management and compliance through agile SaaS-based operations. They understand the value of SaaS, AI, and ML working together,” Behavox Founder and CEO Erkin Adylov said. “As the only vendor who can enable enterprises to aggregate, analyze, and act on data to maintain regulatory compliance, we are committed to helping Danske and other customers uphold their risk management commitments.”
About Behavox Ltd.
Behavox is the leading, end-to-end Data Operating Platform that enables organizations to aggregate, analyze and act on their internal data. As a high-growth technology company, our mission is to organize and make useful all communications data on Earth. Through advanced analytics and machine learning, Behavox is your organization’s single-entry point for internal data.
Behavox, founded in 2014, is headquartered in New York City, with offices in London, Singapore and Montréal. For more information visit here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200602005024/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
The Biggest Predictor of Business Growth Is Behavior30.4.2026 09:00:00 CEST | Press release
New IDEO research reveals a gap in the behaviors that most drive growth: long-term vision, rapid experimentation, and team autonomy—with only 10% of leaders saying their company excels at the combination. IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media &
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 00:22:00 CEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 22:30:00 CEST | Press release
Surgeon-Founded Brand Anchored by Innovative NAC Y2™ Technology The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom